GRAd-COV2

GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera Srl and Lazzaro Spallanzani National Institute for Infectious Diseases.

[2][3] It is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 full length prefusion stabilized Spike protein.

[2] More specifically, the vector used is the simian group C adenovirus GRAd32, isolated from a captive gorilla, with a genome deleted of the entire E1 and E3 regions and the native E4 region replaced with the E4 orf6 of human adenovirus 5 (hAd5).

You can help Wikipedia by expanding it.This article about COVID-19 vaccines is a stub.

You can help Wikipedia by expanding it.

Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.